MTOR and breast carcinoma: Oleocanthal treatment (10 μM) caused a marked downregulation of the phosphorylated mTOR (p-mTOR) in a metastatic breast cancer cell line (MDA-MB-231), suggesting that the anti-carcinogenic activity of oleocanthal is potentially mediated by mTOR inhibition [64].